Skip to main content
. 2024 Dec 18;24:905. doi: 10.1186/s12888-024-06346-2

Table 1.

Comparisons of demographic and clinical variables among groups (early responders vs. final responders vs. non-responders)

Variables Early responders
(n = 35)
final responders
(n = 22)
Non-responders
(n = 33)
Statistic
N (%) N(%) N (%) χ2 p
Male a 12(34.3%) 1(4.6%) 3(9.1%) 7.439 0.007
Psychotic symptoms 5(14.3%) 4(18.3%) 10(30.3%) 2.625 0.279
Drinking a 2(5.7%) 6(27.3) 9(27.3%) 7.037 0.028
Experience of child-parent separation 21(60.0%) 17(77.3%) 13(39.4%) 7.972 0.019
Treatment regimens 4.932 0.300
aiTBS 8(22.9%) 9(40.9%) 14(42.4%)
iTBS 11(31.4%) 7(31.8%) 11(33.3%)
Sham 16(45.7%) 6(27.3%) 8(24.2%)
Antidepressanta 24(68.6%) 17(77.3%) 27(81.8%) 1.660 0.471
Antipsychotic 10(28.6%) 7(31.8%) 7(21.2%) 0.866 0.684
Benzodiazepine 11(31.4%) 14(63.6%) 15(45.5%) 5.697 0.064
Mean ± SD Mean ± SD Mean ± SD F/χ2 p
Age (years)) 15.60 ± 2.71 15.45 ± 2.76 14.24 ± 1.86 2.986 0.056
Education (years) 9.80 ± 2.37 9.50 ± 2.84 8.36 ± 1.64 3.667 0.030
Disease duration (months) b 23.71 ± 27.60 25.91 ± 23.06 18.88 ± 14.89 1.443 0.486
MT(%) 53.54 ± 4.39 51.82 ± 5.15 49.61 ± 5.85 4.968 0.009

Fluoxetine equivalent

(mg/day) b

28.34 ± 63.28 30.30 ± 87.68 31.82 ± 102.26 0.613 0.736
Chlorpromazine equivalent (mg/day) b 15.75 ± 13.82 17.88 ± 14.03 19.82 ± 12.78 4.063 0.131
HAMD-17 22.40 ± 6.15 24.86 ± 5.94 22.61 ± 6.21 1.248 0.292
HAMA 23.57 ± 8.65 29.68 ± 7.76 25.76 ± 8.00 3.753 0.027
GAF 48.71 ± 7.70 45.00 ± 10.24 52.88 ± 10.23 4.836 0.010
NSSI-behaviorb 9.05 ± 7.76 14.85 ± 10.21 16.11 ± 11.84 8.530 0.014
NSSI-function b 28.10 ± 13.02 35.10 ± 10.83 30.64 ± 12.44 4.670 0.097

Abbreviations: aiTBS Accelerated intermittent Theta Burst Stimulation, MT Motor Threshold, HAMD-17 17-item Hamilton Depression Rating Scale, HAMA Hamilton Anxiety Rating Scale, GAF Global Assessment of Function, NSSI Non-suicidal Self-Injury

aFisher exact test

bKruskal-Wallis test